Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Letermovir as cytomegalovirus prophylaxis in children undergoing allogeneic hematopoietic cell transplantation

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Plasma CMV viral load (IU/mL) as assessed by real-time PCR.

References

  1. Annaloro C, Serpenti F, Saporiti G, Galassi G, Cavallaro F, Grifoni F, et al. Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications. Front Immunol. 2021;11:569381.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, et al. Evidence for a Bidirectional Relationship between Cytomegalovirus Replication and acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2010;16:1309–14.

    Article  PubMed  Google Scholar 

  3. Qayed M, Khurana M, Hilinski J, Gillespie S, McCracken C, Applegate K, et al. Risk for CMV reactivation in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2015;62:364–6.

    Article  PubMed  Google Scholar 

  4. Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020;135:1619–29.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010;54:1290–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017;377:2433–44.

    Article  CAS  PubMed  Google Scholar 

  7. César T, Le MP, Klifa R, Castelle M, Fournier B, Levy R, et al. Letermovir for CMV Prophylaxis in Very High-Risk Pediatric Hematopoietic Stem Cell Transplantation Recipients for Inborn Errors of Immunity. J Clin Immunol. 2024;44:1–9.

    Article  Google Scholar 

  8. Chavaz L, Royston L, Masouridi-Levrat S, Mamez A, Giannotti F, Morin S, et al. CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients. Open Forum Infect Dis. 2023;10:ofad169.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Marty FM, Ljungman PT, Chemaly RF, Wan H, Teal VL, Butterton JR, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020;20:1703–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

TP, CRL and AG conceived and designed the retrospective study. Patient enrollment and management: TP, CRL, SS, MM, RH, JB, AG. Analysis and interpretation of data: TP, AG, CRL. Writing of the manuscript: TP, CRL, AG. Review/revision of the manuscript: all authors.

Corresponding author

Correspondence to Thomas Pfeiffer.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pfeiffer, T., Lockowitz, C.R., Shenoy, S. et al. Letermovir as cytomegalovirus prophylaxis in children undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02315-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41409-024-02315-1

Search

Quick links